Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MAIA MAIA Biotechnology Inc
- Stocks
- Healthcare
- NYSEAMERICAN: MAIA
Price (delayed)
$1.8
Market cap
$54.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.79
Enterprise value
$43.69M
We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In
Highlights
MAIA's equity has surged by 186% year-on-year and by 36% since the previous quarter
The EPS has surged by 50% year-on-year and by 25% since the previous quarter
MAIA Biotechnology's quick ratio has increased by 27% YoY but it has decreased by 14% from the previous quarter
Key stats
What are the main financial stats of MAIA
Market
Valuations
Earnings
Shares outstanding
30.31M
Market cap
$54.55M
Enterprise value
$43.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
10.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$18.43M
Net income
-$19.7M
EBIT
-$19.7M
EBITDA
-$19.7M
Free cash flow
-$16.32M
Per share
Balance sheet
Liquidity
EPS
-$0.79
EPS diluted
-$0.79
Free cash flow per share
-$0.59
Book value per share
$0.17
Revenue per share
$0
TBVPS
$0.43
Total assets
$11.86M
Total liabilities
$6.92M
Debt
$0
Equity
$4.94M
Working capital
$6.8M
Debt to equity
0
Current ratio
2.35
Quick ratio
2.15
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-182.1%
Return on equity
-590.1%
Return on invested capital
N/A
Return on capital employed
-289.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MAIA stock price
How has the MAIA Biotechnology stock price performed over time
Intraday
1.69%
1 week
-11.76%
1 month
16.88%
1 year
-42.31%
YTD
-9.09%
QTD
17.65%
Financial performance
How have MAIA Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.43M
Net income
-$19.7M
Gross margin
N/A
Net margin
N/A
MAIA Biotechnology's net income has increased by 17% YoY and by 15% from the previous quarter
MAIA Biotechnology's operating income has decreased by 9% from the previous quarter but it has increased by 8% YoY
Price vs fundamentals
How does MAIA's price correlate with its fundamentals
Growth
What is MAIA Biotechnology's growth rate over time
Valuation
What is MAIA Biotechnology stock price valuation
P/E
N/A
P/B
10.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 50% year-on-year and by 25% since the previous quarter
MAIA's equity has surged by 186% year-on-year and by 36% since the previous quarter
The stock's price to book (P/B) is 51% less than its last 4 quarters average of 22.0
Efficiency
How efficient is MAIA Biotechnology business performance
The company's return on equity has surged by 83% QoQ and by 73% YoY
The return on assets is up by 36% year-on-year and by 21% since the previous quarter
Dividends
What is MAIA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MAIA.
Financial health
How did MAIA Biotechnology financials performed over time
MAIA's total assets is 71% greater than its total liabilities
MAIA Biotechnology's total liabilities has plunged by 52% YoY but it has increased by 6% from the previous quarter
MAIA's total assets is up by 36% year-on-year and by 17% since the previous quarter
The debt is 100% less than the equity
MAIA's equity has surged by 186% year-on-year and by 36% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.